Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1434)
Drug Name
Roflumilast
Synonyms
Roflumilast; Roflumilast (Daxas); 0P6C6ZOP5U; 162401-32-3; 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE; Daliresp; Libertek; 3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide; AK110425; B 9302-107; B9302-107; BY 217; BY-217; BY217; BYK 20869; BYK-20869; BYK20869; Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-; CHEBI:47657; CHEMBL193240; DAXAS; ROF; UNII-0P6C6ZOP5U
Indication Chronic obstructive pulmonary disease [ICD11: CA22] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 403.2 Topological Polar Surface Area 60.4
Heavy Atom Count 26 Rotatable Bond Count 7
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 6
Cross-matching ID
PubChem CID
449193
PubChem SID
7890296 ; 10300323 ; 12014977 ; 14879303 ; 36890842 ; 46393569 ; 46393577 ; 46515099 ; 47207405 ; 49876227 ; 50659842 ; 53788863 ; 57288829 ; 57404909 ; 58108277 ; 85239858 ; 87235814 ; 103463298 ; 104253463 ; 104640579 ; 109693509 ; 121279025 ; 124757594 ; 124772083 ; 125001902 ; 125164398 ; 125536640 ; 126618387 ; 126666054 ; 126731090 ; 128619725 ; 134339138 ; 134339348 ; 134339400 ; 134358320 ; 135114471 ; 136345716 ; 136946527 ; 137010091 ; 137269493 ; 142175980 ; 144223762 ; 160644734 ; 162011650 ; 162037767 ; 162201204 ; 163124095 ; 163406034 ; 163620892 ; 163686213
ChEBI ID
CHEBI:47657
CAS Number
162401-32-3
TTD Drug ID
D0R4UW
Formula
C17H14Cl2F2N2O3
Canonical SMILES
C1CC1COC2=C(C=CC(=C2)C(=O)NC3=C(C=NC=C3Cl)Cl)OC(F)F
InChI
1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
InChIKey
MNDBXUUTURYVHR-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Roflumilast N-oxide DM015571
9940999
Oxidation - N-oxidation 1 [2] , [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR009562 Roflumilast Roflumilast N-oxide Oxidation - N-oxidation CYP3A4 ... [2], [3]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
References
1 Roflumilast was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. J Clin Pharmacol. 2011 Apr;51(4):586-93.
3 A Single-center, Open-label, Parallel Control Study Comparing the Pharmacokinetics and Safety of a Single Oral Dose of Roflumilast and Its Active Metabolite Roflumilast N-oxide in Healthy Chinese and Caucasian Volunteers

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.